TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: EXCEL class attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preoperative variations in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the concentration-time curve (0 to last quantifiable concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (0 to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC QLQ-INFO25 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Systolic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Guideline-concordant care at the institutional level
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient perception of care coordination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient perception of self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of product application
Endpoint domain: Adverse events/effects
Primary endpoint: Montreal cognitive assessment score (MOCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of life in Parkinson's disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of spot sign on gadolinium MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myofibrillar protein fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Amino Acid Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histopathological evaluation of PDO and tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nature of the cord vocal lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ptdi swing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post Thrombotic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Completion of self-report data-collection booklet denoting ONS consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily consumption of Oral Nutritional Supplementation as per prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treat-to-target after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of greater than or equal to (≥) 5% weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in TETRAS composite outcome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jaw Functional Limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Hamilton Depression Rating Scale-24 item (HAMD-24)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: the Cox Menstrual Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work Productivity and Activity Impairment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who complete neuropsychological testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients who complete telehealth neuropsychological testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: final implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Modified Symptom Assessment in Dry Eye Questionnaire, Global Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of organoids and clinical patient responses to drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-rabies vaccination compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Attendance Rate of CALM Breathing Treatment Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Drop-Out Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CALM Breathing Satisfaction Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Force generation by lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients screened for opioid use disorder (OUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients initiated on medications for OUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients screened for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients initiated on antiretroviral medication (ART) for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients screened for Hepatitis C (HCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients initiated on medication for HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trafficking of anti-BCMA CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarkers of YKL40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutritional status and body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of zilucoplan (ZLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in sheep red blood cell (sRBC) lysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in complement component 5 (C5) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patients' adherence to the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in severity of CIPN
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postprandial plasma amino acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Billed Advance Care Planning
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Merit-based Incentive Payment System Advance Care Planning Quality Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glasgow Depression Scale for Intellectual Disability (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety Depression and Mood Scale (ADAMS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mood, Interest, & Pleasure Questionnaire (MIPQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RSN-FC assessed through HD-EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RSN-FC assessed through MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: gapCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User satisfaction rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients who were hospitalized
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients who received sustained rate-reduction medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients who received stroke prevention interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Adherence to HIV medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Adherence based on HIV appointments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline performance on untrained IADL tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in systolic 24-hour blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Humoral and cellular responses to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mouthdrying Just Noticeable Difference Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent time in target range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Production of indole precursor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: modified meibomian gland score (mMGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart function measurement for congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scar adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximum concentrations (Cmax) of JAB-21822
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of JAB-21822
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve from dose to infinity (AUC0-∞) of JAB-21822
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teen-reported insomnia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teen-reported treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of bleeding events grade 3 and 4
Endpoint domain: Adverse events/effects
Primary endpoint: Youth Services Survey-Families (YSS-F)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma total protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with COVID-19 progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Telephone Montreal Cognitive Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Every Day Cognition-12
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: miRNA-223 & -214 levels in GCF samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daily meat consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum sestrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour burden
Endpoint domain: Mortality/survival
Primary endpoint: Treatment Credibility/Expectancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of humoral rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous Vaginal Delivery
Endpoint domain: Mortality/survival
Primary endpoint: Functional and morphological properties of arterial wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Concentration of Lp (a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased QT interval (more than 500 ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: alanine aminotransferase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiotracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in target range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular events and all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients recruited to virtually-delivered exercise intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients who achieve study adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: abnormal inflammatory activity in the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: converted resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diurnal phase shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC Subjective Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Strength of Flexors and Extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AP Translation (anterior-posterior)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction of program as assessed by the Client Satisfaction Questionnaire (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in plasma triglycerides level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain postoperative improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the curve of branched-chain amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in musculoskeletal disorders of the upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle activity of Supraspinatus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing process and duration of cold sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood beta-hydroxybutyrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival of mechanical cardiovascular resuscitation
Endpoint domain: Mortality/survival
Primary endpoint: soreness measured by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soreness measured by force algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital game and subcutaneous injection skill level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of satisfaction and self-confidence in digital gaming and learning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rate of cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive Agreement Rate (PPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relevant biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neonatal hypoglycemia on day 0 of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time interval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Invasive or non-invasive ventilation use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of treatment-based adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Isometric Quad strength Peak Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic Quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: return to sensory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PNS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ophthalmic morphological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: organ damage or safety concerns
Endpoint domain: Adverse events/effects
Primary endpoint: Positivity of lesions detected by 68Ga-NY104 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positivity of lesions detected by 18F-FDG PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in number of leakages of continence pads per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIME
Endpoint domain: General outcomes
Primary endpoint: Highly sensitive CRP (HS-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total leucocytic count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improper bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of COVID-19 infection after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in perceived stability of cognitive status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cmax of perindopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of active metabolite perindoprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72 of perindopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72 of active metabolite perindoprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total score on the Michigan Diabetic Neuropathy Score (MDNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetic (PK) profile of LP-168
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from Baseline in WHO-5 Well-Being Index at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in WHO-5 Well-Being Index at 8 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak opioid withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of time to reach 8mg of buprenorphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients who decide to join in a clinical study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Rosacea patients who remain in clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Connectivity measures of the left TGd, 55b, and STV parcellations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Face Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale (Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional impact of intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Specific pain related to laparoscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy Episodic Drinking (HED) Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal butyrate over urine p-cresol sulfate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients alive without progression
Endpoint domain: Mortality/survival
Primary endpoint: Iowa gambling task (IGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient and nurse satisfaction with chemotherapy procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: free T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of patients with improved symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hemidiaphragmatic paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Eye-hand Proximity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes